The Global Alzheimer’s Platform Foundation® (GAP) is pleased to announce a collaboration with the Biomarkers of Aging Consortium, a consortium dedicated to the developing and validating biomarkers for ...

Two new PET radiotracers have outperformed the only current Food and Drug Administration (FDA) approved radiotracer for ...

Lantheus' oncology portfolio includes Pylarify (piflufolastat F 18) and a growing pipeline addressing various solid tumours.

A delay in getting to the rapid eye movement (REM) stage of sleep may be linked to Alzheimer's disease and related dementias, ...

First patients with memory problems join ‘revolutionary’ trial by Oxford and Cambridge universities which could lead to ‘Holy ...

Research indicates longer REM latency is associated with higher Alzheimer's biomarkers, pointing to its potential as an early ...

A new clinical study has started this week, looking at whether a blood test can help diagnose dementia earlier on.

Access to the new Alzheimer's drugs is limited by strict eligibility criteria, long wait times, and a lack of infusion ...

There are two kinds of risk factors for dementia: non-modifiable and modifiable. Non-modifiable risk factors are ones that cannot be changed or eliminated, like aging, family history and genetics.

However, in people with mild cognitive impairment, the presence of depressive symptoms was tied to a lower likelihood of amyloid pathology (OR 0.73, 95% CI 0.61-0.89, P =0.001), Oomens and colleagues ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

FirstHealth Moore Regional Hospital announces the availability of PET Amyvid brain scans, a cutting-edge diagnostic tool ...